Cadila Healthcare gets EIR report on Ahmedabad SEZ facility
New Delhi: Drug firm Cadila Healthcare Monday said it has received establishment inspection report from the US health regulator with voluntary action indicated (VAI) classification for its Ahmedabad SEZ facility.
The United States Food and Drug Administration (USFDA) had conducted an inspection of the company's formulations manufacturing facility located at SEZ, Ahmedabad from March 25 to April 3, 2019, Cadila Healthcare said in a BSE filing.
Read Also: Cadila Healthcare gets 11 USFDA observations for St Louis facilities
The plant has received an establishment inspection report (EIR). The EIR report stated that the classification of the facility is VAI, it added.
As per the USFDA, VAI means that though "objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action".
Read Also: Cadila Healthcare posts Q4 net profit of Rs 460 crore
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here